Pharma & Biotech Global Week in Review 21 March 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Nexavar (Sorafenib) – India: Controversial licence granted over patented cancer drug (IP Whiteboard) (IPKat) (Patent Law Practice Center) (Patent Docs) (Patent Baristas) (Patent Baristas)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

What limitations does TRIPS put on compulsory licensing? (IPKat)

Who is Sally Susman, and why does she want poor people to pay higher prices for medicines? (KEI)

WHO under siege by private sector, group asserts (IP Watch)

India: Some interesting facts about the Indo-E.U. dispute over the seizure of ‘in-transit’ pharmaceuticals (Spicy IP)

Norway: Borgarting Appelate Court dismissed Pharmaq’s claim that Intervet’s patent claiming deposited virus strains was invalid and that its vaccine did not infringe (Kluwer Patent Blog)

US: Importing drugs from Canada for personal use? (Patently-O)

US: “Public interest” groups call for synthetic biology regulation (Patent Docs)

US: Bayer CropScience files patent infringement complaint against Dow Agrosciences over glyphosate resistant transgenic plants/seeds (Patent Docs)

 

Products

Fusilev (Levoleucovorin) – US: Spectrum Pharmaceuticals files patent infringement complaint against InnoPharma in response to Para IV challenge (Patent Docs)

Gleevec (Imatinib) – India: Patent “ever-greening”: Novartis confronts patent myth in India (BIOtechNOW)

Gralise (Gabapentin) – US: Depomed files patent infringement suit against Actavis Elizabeth in response to Para IV challenge (Patent Docs)

Januvia (Sitagliptin) – EU: CJEU: Art 13 of old SPC Regulation in conjunction with Art 36 Pediatric Regulation allow for grant of SPC of negative duration: Merck Sharp & Dohme Corp v Deutsches Patent- und Markenamt (Kluwer Patent Blog)

Nexavar (Sorafenib) – India: Controversial licence granted over patented cancer drug (IP Whiteboard) (IPKat) (Patent Law Practice Center) (Patent Docs) (Patent Baristas) (Patent Baristas)

Niaspan (Niacin) – US: Abbott files patent infringement complaint against Mylan in response to Para IV challenge (Patent Docs)

Nuedexta (Dextromethorphan) – US: Avanir files patent infringement complaint against Watson Pharma in response to Para IV challenge (Patent Docs)

Qlaira (Dienogest and Estradiol Valerate) – Poland: Warsaw District Administrative Court upholds Polish Patent Office’s “no” to Qlaira SPC (The SPC Blog)

Seroquel / Seroquel XR (Quetiapine fumarate) – US: AstraZeneca sues FDA over generic Seroquel labeling carve-out issue after FDA issues non-response citizen petition denial (FDA Law Blog)

Singulair (Montelukast) – US: Merck Frosst Canada files patent infringement complaint against Dr Reddy’s in response to Para IV challenge (Patent Docs)

Stelara (Ustekinumab) – US: District Court Massachusetts decision in case involving Centocor’s IL-12 antibody Stelara: Abbott v Centocor (Holman’s Biotech IP Blog)

Viagra (Sildenafil) – China: Pfizer loses yet another Viagra trademark dispute in China (China Hearsay)

Zinc – UK: EWHC (Ch) upholds UK IPO rejection of patent application for treatment of inflammatory bowel disease (IBD) with zinc: El-Tawil v The Comptroller General of Patents (Kluwer Patent Blog)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: